A First-in-human Study of KK8123 in Adults With X-linked Hypophosphatemia — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(9 sites)
United States
University of California - San Francisco, San Francisco, California Yale Center for XLH/ Yale University School of Medicine, New Haven, Connecticut Indiana University School of Medicine University Hospital, Indianapolis, Indiana Mayo Clinic, Rochester, Minnesota Vanderbilt University Medical Center, Nashville, Tennessee France
Hoptial Bictre, Le Kremlin-Bicêtre, Paris Germany
Institute of Osteology and Biomechanics (IOBM), Hamburg Universitaetsklinikum Wurzburg, Würzburg Spain
Hospital Universitario La Paz, Madrid Last updated November 2025